Bitcoin halving
What does that mean?
$2.78T
Total marketcap
$123.48B
Total volume
BTC 49.88%     ETH 15.34%
Dominance

ACADIA Pharmaceuticals ACAD Stock

18.23 USD {{ price }} 0.164828% {{change_pct}}%
Exchange
NasdaqGS
Market Cap
3B USD
LOW - HIGH [24H]
18.05 - 18.3 USD
VOLUME [24H]
156.19K USD
{{ volume }}
P/E Ratio
0
Earnings per share
-0.37 USD

ACADIA Pharmaceuticals Price Chart

ACADIA Pharmaceuticals ACAD Financial and Trading Overview

ACADIA Pharmaceuticals stock price 18.23 USD
Previous Close 24.14 USD
Open 24.15 USD
Bid 0 USD x 1100
Ask 0 USD x 1000
Day's Range 24.07 - 24.58 USD
52 Week Range 12.24 - 26.04 USD
Volume 1.06M USD
Avg. Volume 1.41M USD
Market Cap 3.97B USD
Beta (5Y Monthly) 0.525352
PE Ratio (TTM) N/A
EPS (TTM) -0.37 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 23.98 USD

ACAD Valuation Measures

Enterprise Value 3.73B USD
Trailing P/E N/A
Forward P/E 2439
PEG Ratio (5 yr expected) -1.79
Price/Sales (ttm) 7.62438
Price/Book (mrq) 10.581345
Enterprise Value/Revenue 7.167
Enterprise Value/EBITDA -22.982

Trading Information

ACADIA Pharmaceuticals Stock Price History

Beta (5Y Monthly) 0.525352
52-Week Change 25.01%
S&P500 52-Week Change 20.43%
52 Week High 26.04 USD
52 Week Low 12.24 USD
50-Day Moving Average 22 USD
200-Day Moving Average 18.47 USD

ACAD Share Statistics

Avg. Volume (3 month) 1.41M USD
Avg. Daily Volume (10-Days) 1.19M USD
Shares Outstanding 162.62M
Float 110.72M
Short Ratio 6.54
% Held by Insiders 0.22%
% Held by Institutions 97.70%
Shares Short 10.04M
Short % of Float 8.27%
Short % of Shares Outstanding 6.16%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin -28.053%
Operating Margin (ttm) -31.55%
Gross Margin 29.07%
EBITDA Margin -31.18%

Management Effectiveness

Return on Assets (ttm) -16.037%
Return on Equity (ttm) -35.63%

Income Statement

Revenue (ttm) 520.23M USD
Revenue Per Share (ttm) 3.21 USD
Quarterly Revenue Growth (yoy) 2.60%
Gross Profit (ttm) 145.49M USD
EBITDA -162228000 USD
Net Income Avi to Common (ttm) -145940000 USD
Diluted EPS (ttm) -0.93
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 402.87M USD
Total Cash Per Share (mrq) 2.48 USD
Total Debt (mrq) 60.61M USD
Total Debt/Equity (mrq) 16.2 USD
Current Ratio (mrq) 2.242
Book Value Per Share (mrq) 2.305

Cash Flow Statement

Operating Cash Flow (ttm) -55639000 USD
Levered Free Cash Flow (ttm) 68.01M USD

Profile of ACADIA Pharmaceuticals

Country United States
State CA
City San Diego
Address 12830 El Camino Real
ZIP 92130
Phone 858 558 2871
Website https://acadia.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 540

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.

Q&A For ACADIA Pharmaceuticals Stock

What is a current ACAD stock price?

ACADIA Pharmaceuticals ACAD stock price today per share is 18.23 USD.

How to purchase ACADIA Pharmaceuticals stock?

You can buy ACAD shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for ACADIA Pharmaceuticals?

The stock symbol or ticker of ACADIA Pharmaceuticals is ACAD.

Which industry does the ACADIA Pharmaceuticals company belong to?

The ACADIA Pharmaceuticals industry is Biotechnology.

How many shares does ACADIA Pharmaceuticals have in circulation?

The max supply of ACADIA Pharmaceuticals shares is 164.77M.

What is ACADIA Pharmaceuticals Price to Earnings Ratio (PE Ratio)?

ACADIA Pharmaceuticals PE Ratio is now.

What was ACADIA Pharmaceuticals earnings per share over the trailing 12 months (TTM)?

ACADIA Pharmaceuticals EPS is -0.37 USD over the trailing 12 months.

Which sector does the ACADIA Pharmaceuticals company belong to?

The ACADIA Pharmaceuticals sector is Healthcare.

ACADIA Pharmaceuticals ACAD included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16389.58 USD
-0.06
1.92B USD 16347.38 USD 16420.92 USD 1.92B USD
Dow Jones U.S. Biotechnology In DJUSBT 2885.94 USD
+0.18
19.02M USD 2878.66 USD 2887.95 USD 19.02M USD
NASDAQ Biotechnology Total Retu XNBI 4776.8 USD
+0.12
4750.07 USD 4787.94 USD
Nasdaq US 700 Small Cap Index NQUS700SC 2191.41 USD
+0.92
2175.22 USD 2191.57 USD
NASDAQ Global Select Market Com NQGS 7970.36 USD
-0.08
7950.14 USD 7986.36 USD
Stlmt ID NASDAQ Biotechnology NBX 4604.4 USD
-2.98
4555.41 USD 4917.8 USD
NASDAQ Composite Total Return I XCMP 19930.13 USD
<0.01
19865.24 USD 19954.6 USD
Nasdaq US Smart Pharmaceuticals NQSSPH 1491.28 USD
+0.38
1484.78 USD 1491.86 USD
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG 2665.89 USD
+0.44
2655.61 USD 2666.96 USD
NASDAQ Biotechnology NBI 4453.76 USD
+0.17
4426.59 USD 4461.88 USD
NASDAQ HealthCare IXHC 1016.59 USD
+0.43
1011.36 USD 1016.61 USD